Lv Meng, Chen Zhuo, Hu Gaoyun, Li Qianbin
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University, 410013 Changsha, Hunan, China.
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University, 410013 Changsha, Hunan, China.
Drug Discov Today. 2015 Mar;20(3):332-46. doi: 10.1016/j.drudis.2014.10.007. Epub 2014 Oct 31.
Diabetic nephropathy (DN) is one of the most common complications of diabetes with high mortality rates worldwide. The treatment of DN has posed a formidable challenge to the scientific community. Simple control of risk factors has been insufficient to cope with the progression of DN. During the process of anti-DN drug discovery, multiple pathogeneses such as oxidative stress, inflammation and fibrosis should all be considered. In this review, the pathogenesis of DN is summarized. The major context focuses on a few small molecules toward the pathogenesis available in animal models and clinical trials for the treatment of DN. The perspectives of novel anti-DN agents and the future directions for the prevention of DN are discussed.
糖尿病肾病(DN)是糖尿病最常见的并发症之一,在全球范围内死亡率很高。DN的治疗给科学界带来了巨大挑战。单纯控制危险因素已不足以应对DN的进展。在抗DN药物研发过程中,应综合考虑氧化应激、炎症和纤维化等多种发病机制。本文综述了DN的发病机制。主要内容聚焦于一些针对动物模型和治疗DN的临床试验中发病机制的小分子药物。讨论了新型抗DN药物的前景以及预防DN的未来方向。